YOLFTbeta
17

Chunghwa Chemical Synthesis & Biotech Co Ltd

1762 · TW · Healthcare / Biotechnology

31.00TWD+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close31.00
Open31.50
Day Range30.25 – 31.65
52-Week Range24.20 – 44.75
Volume92.57K
Market Cap2.61B
P/E (TTM)0.00
Forward P/E0.00
EPS-1.59
Dividend Yield0.00%
Beta0.50
50-Day Avg34.46
200-Day Avg31.81

About

Chunghwa Chemical Synthesis & Biotech Co., Ltd. engages in the manufacturing, sale, and wholesale of western medicine in Taiwan and internationally. The company offers biotechnology products, including Anidulafungin antifungal medication, Caspofungin Acetate antifungal medication, Dalbavancin Hydrochloride Bacterial Skin Infection Drug, Everolimus, immunosuppressant and anticancer drug), Midostaurin for treating acute myeloid leukemia, Pneumocandin B0 antifungal intermediate, Rapamycin, Rezafungin acetate antifungal medication, Semaglutide weight loss medication, and Tacrolimus immunosuppressant, as well as Mycophenolate Mofetil, Mycophenolate Mofetil HCl, and Mycophenolate Sodium immunosuppressive drugs. It also provides non-biotechnology products, such as Abaloparatide osteoporosis medication, Baricitinib rheumatoid arthritis medication, Brivaracetam antiepileptic drug, Difelikefalin Acetate Pruritus, Edoxaban Tosylate Monohydrate, Eltrombopag Olamine, Eslicarbazepine Actate, Ethyl Icosapentate, Lanreotide Acetateacromegaly), Ozanimod HCl medicine for multiple sclerosis, Ribociclib for breast cancer medication, Plecanatide chronic idiopathic constipation medication, Ribociclib breast cancer medication, Selumetinib Sulfate for neurofibromatosis, Setmelanotide Acetate genetic obesity drug, Sugammadex Sodium anesthesia recovery medication, Tofacitinib Citrate rheumatoid arthritis medication, Trandolapril antihypertensive medication, Trilaciclib Dihydrochloride bone marrow protectant, Tenapanor HCl medication for constipation-predominant irritable bowel syndrome and hyperphosphatemia in dialysis patients. The company was formerly known as China Chemical Synthesis Industry Co., Ltd. and changed its name to Chunghwa Chemical Synthesis & Biotech Co., Ltd. in January 2003. Chunghwa Chemical Synthesis & Biotech Co., Ltd. was founded in 1964 and is headquartered in New Taipei City, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Qing-Peng Wei
  • Employees0
  • Headquarters1, Tung-Hsing St., New Taipei City, Taiwan, 23850, Taiwan
  • Websitehttps://www.ccsb.com.tw

Leadership

  • Mr. Qing-Peng WeiGeneral Manager
  • Mr. Kuan-Chieh WangManager of Finance Department & Head of Corporate Governance
  • Guanjie WangAccounting Supervisor
  • Mr. Jun-Jie LiaoManager of Human Resource Office
  • Mr. Chao-Sheng HongChief Auditor

Financials

Income Statement

Currency: TWD2008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue850.76M1.13B1.20B1.20B1.33B1.04B946.70M1.16B1.20B1.17B1.02B1.16B1.54B1.93B2.12B2.09B1.35B804.88M
Growth (%)-+32.45%+6.25%+0.28%+10.75%-21.52%-9.27%+22.76%+3.14%-2.54%-12.74%+13.46%+33.45%+25.34%+9.43%-1.45%-35.42%-40.26%
Cost of Revenue462.60M598.40M745.35M747.08M809.29M668.49M649.95M755.74M784.21M760.38M667.94M688.01M856.84M985.31M1.16B1.33B953.06M813.74M
Gross Profit-528.45M451.89M453.50M520.30M374.99M296.76M406.47M414.46M407.87M351.51M468.63M686.75M949.39M961.76M757.31M394.32M-8.86M
Gross Margin-46.90%37.74%37.77%39.13%35.94%31.35%34.97%34.58%34.91%34.48%40.52%44.49%49.07%45.43%36.30%29.27%-1.10%
Operating Expense-230.50M246.24M284.94M294.38M276.26M273.41M306.96M316.33M329.73M320.62M314.27M31.70M430.11M387.08M476.50M387.98M310.67M
Operating Income139.15M297.96M205.65M168.55M225.91M98.73M23.35M99.52M98.13M78.14M30.89M154.36M655.05M519.28M574.67M280.81M6.34M-319.54M
Operating Margin16.36%26.44%17.18%14.04%16.99%9.46%2.47%8.56%8.19%6.69%3.03%13.35%42.44%26.84%27.14%13.46%0.47%-39.70%
EBITDA-354.63M348.31M261.56M289.80M182.00M148.42M447.31M214.36M252.01M165.73M250.75M786.21M651.27M743.72M545.93M277.66M-47.60M
EBITDA Margin-31.47%29.09%21.79%21.80%17.44%15.68%38.49%17.88%21.57%16.26%21.68%50.93%33.66%35.13%26.17%20.61%-5.91%
Net Income122.42M245.10M187.00M170.99M175.56M96.83M14.59M308.36M60.28M85.77M234.25M117.00M531.87M400.78M465.87M264.91M53.03M-243.85M
Net Income Margin14.39%21.75%15.62%14.24%13.20%9.28%1.54%26.53%5.03%7.34%22.98%10.12%34.46%20.72%22.00%12.70%3.94%-30.30%
R&D89.33M105.67M100.80M130.49M136.31M126.48M130.02M131.87M146.40M149.32M161.54M195.46M215.73M252.67M244.79M242.70M205.84M168.35M
R&D as % of Total Revenue10.50%9.38%8.42%10.87%10.25%12.12%13.73%11.35%12.21%12.78%15.85%16.90%13.98%13.06%11.56%11.63%15.28%20.92%
Interest Expense019.17M10.09M2.27M9.79M12.32M14.02M8.37M6.56M8.35M10.87M10.62M4.76M3.32M9.71M19.44M21.29M16.73M
Interest Expense % of Total Revenue0.00%1.70%0.84%0.19%0.74%1.18%1.48%0.72%0.55%0.71%1.07%0.92%0.31%0.17%0.46%0.93%1.58%2.08%

Balance Sheet

Currency: TWD2008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets2.28B2.31B2.37B2.38B3.02B3.04B3.21B2.87B2.73B3.45B3.22B3.44B3.15B4.38B4.56B5.17B4.76B4.32B
Total Liabilities1.44B1.12B687.80M698.59M1.34B1.33B1.59B1.01B954.48M1.63B1.24B1.42B648.48M1.49B1.37B1.82B1.41B1.23B
Total Equity808.94M1.16B1.60B1.60B1.68B1.65B1.57B1.84B1.77B1.82B1.98B2.01B2.50B2.89B3.19B3.35B3.36B3.09B
Cash46.56M188.00M345.79M226.43M120.11M211.49M221.46M190.27M143.08M156.00M106.37M101.22M148.63M195.25M300.61M269.57M222.28M216.44M
Total Debt-489.77M70.00M179.98M779.96M910.23M1.15B560.23M510.24M1.19B798.59M896.30M4.29M753.55M604.54M1.21B858.17M805.86M
Net Debt-301.78M-275.79M-46.45M659.85M698.75M929.23M369.96M367.16M1.03B692.22M795.08M-144.34M558.30M303.93M939.54M635.89M589.42M

Cash Flow

Currency: TWD2008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow75.39M462.07M275.61M144.84M268.46M145.24M23.08M79.70M261.31M159.34M234.66M268.13M138.24M219.18M733.78M-77.50M467.65M142.61M
Investing Cash Flow--34.07M66.56M-64.59M-758.32M-119.90M-160.70M533.67M-131.49M-786.14M146.41M-269.27M865.03M-802.75M-376.18M-461.32M-100.10M-61.80M
Financing Cash Flow--283.90M-182.75M-200.14M513.64M-43.67M146.88M-645.25M-176.79M641.35M-431.34M-3.50M-954.85M630.62M-253.32M496.57M-415.72M-86.03M
Capital Expenditure42.12M36.55M51.50M67.12M762.95M110.04M146.59M129.28M114.86M805.80M93.73M114.80M192.98M405.45M376.18M450.00M104.69M62.33M
Free Cash Flow-425.52M224.12M77.72M-494.49M35.20M-123.51M-49.57M146.46M-646.46M140.94M153.33M-54.75M-186.27M357.60M-517.83M362.96M80.28M
Dividends Paid--175.50M155.12M116.34M116.34M93.00M38.78M116.34M38.78M38.78M93.07M62.05M116.34M100.83M100.83M62.05M14.74M
FCF to OCF-92.09%81.32%53.66%-184.19%24.23%-535.11%-62.20%56.05%-405.71%60.06%57.19%-39.61%-84.99%48.73%668.14%77.61%56.29%
Dividend Paid to FCF--78.31%199.58%-23.53%330.55%-75.30%-78.23%79.44%-6.00%27.52%60.70%-113.33%-62.46%28.20%-19.47%17.09%18.36%

Earnings

Report DateJun 30, 2010Dec 1, 2010Mar 2, 2011Apr 26, 2011Aug 31, 2011Oct 30, 2011Mar 29, 2012May 30, 2012Aug 29, 2012Oct 31, 2012Mar 29, 2013May 29, 2013Aug 28, 2013Nov 27, 2013Feb 26, 2014May 15, 2014Aug 14, 2014Nov 14, 2014Feb 25, 2015May 15, 2015Aug 13, 2015Nov 12, 2015Mar 30, 2016May 12, 2016Aug 11, 2016Nov 11, 2016Mar 30, 2017May 15, 2017Aug 11, 2017Nov 14, 2017Mar 30, 2018May 14, 2018Aug 14, 2018Nov 14, 2018Mar 29, 2019May 1, 2019Aug 14, 2019Nov 14, 2019Mar 31, 2020May 15, 2020Aug 13, 2020Nov 13, 2020Mar 4, 2021May 14, 2021Aug 13, 2021Nov 8, 2021Mar 8, 2022May 13, 2022Aug 12, 2022Nov 11, 2022Mar 31, 2023May 9, 2023Aug 11, 2023Nov 13, 2023Mar 11, 2024May 15, 2024Aug 13, 2024Nov 11, 2024Nov 14, 2025Mar 31, 2026
EPS Estimate---0.68-0.630.76--0.730.73----0.280.52------0.450.280.31--0.050.340.600.520.160.280.350.430.430.400.48-0.380.700.551.151.021.241.421.451.021.561.190.902.001.140.620.910.150.66--0.22-0.20
EPS Actual1.120.680.810.570.480.600.680.471.160.540.100.540.580.090.030.150.31-0.280.012.580.170.410.800.220.000.180.37-0.15-0.160.800.610.050.192.83-0.07-0.070.170.330.470.364.780.441.231.261.621.091.161.631.901.540.902.290.380.150.570.520.27-0.11-0.77-2.55
Surprise----16.18%--4.76%-10.53%---26.03%-86.30%-----46.43%-40.38%-------51.11%-99.46%-41.94%--200.00%-147.06%33.33%17.31%-68.75%-32.14%708.57%-116.28%-116.28%-57.50%-31.25%--5.26%582.86%-20.00%6.96%23.53%30.65%-23.24%-20.00%59.80%21.79%29.41%0.00%14.50%-66.67%-75.81%-37.36%246.67%-59.09%--250.00%-1175.00%
Timing---After-hours-After-hoursAfter-hours--After-hoursAfter-hours----Pre-marketPre-marketPre-market-Pre-marketPre-marketAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap2.61B
Enterprise Value3.01B
Trailing P/E0.00
Forward P/E0.00
PEG Ratio0.00
Price / Sales2.79
Price / Book0.81
EPS-1.59
Book Value41.64
Revenue (TTM)934.29M
Gross Profit (TTM)167.67M
EBITDA49.99M
Profit Margin-5.53%
Operating Margin11.55%
Return on Equity-1.60%
Return on Assets-1.91%
Shares Outstanding76.92M
Shares Float46.05M
Beta0.50
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio145.45%

Dividends

20231×
1.30Jul 24, 2023
20221×
1.30Jul 22, 2022
20211×
1.50Jul 22, 2021
20201×
0.80Jul 23, 2020
20191×
1.20Jul 24, 2019
20181×
0.50Jul 24, 2018
20171×
0.50Jul 24, 2017
20161×
1.50Jul 22, 2016
20151×
0.50Jul 23, 2015
20141×
1.00Jul 28, 2014
20131×
1.50Jul 18, 2013
20121×
1.50Jul 19, 2012
20111×
2.00Jul 11, 2011
20101×
2.50Jul 6, 2010